Q4 2025 Management View CEO David Endicott emphasized that "the second half of 2025 and especially the fourth quarter demonstrated the strength and momentum of our business." He highlighted recent ...

“Alcon has a long legacy of advancing phaco and vitreoretinal technology for surgical ophthalmology. With UNITY VCS/CS, we are introducing more than a dozen innovations designed to transform surgical ...

Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada New, proprietary technology is designed to deliver significant surgical and workflow efficiencies First innovation to be ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted 510(k) clearance to Alcon’s Unity combined vitreoretinal cataract system and stand-alone ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced results from time and motion studies demonstrating superior efficiency* with UNITY® ...

Investing.com -- Bank of America double downgraded Alcon to Underperform and cut its price objective to 60 CHF from 80 CHF, citing weaker visibility on growth and a slower than expected ramp in Unity ...

TORONTO--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY ® Vitreoretinal Cataract System (VCS) has received Health Canada ...

GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the UNITY ® Vitreoretinal Cataract System (VCS) and UNITY ® ...

“Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us ...